A Randomized, Controlled Trial of [amount hidden] of Liraglutide in Weight Management

What Was Tested

The paper reports a study of Liraglutide, published as a randomized controlled trial.

Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone.

Who Took Part

The study group was 3731 patients.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

The researchers conducted a 56-week, double-blind trial involving 3731 patients who did not have type 2 diabetes and who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 30 or a BMI of at least 27 if they had treated or untreated dyslipidemia or hypertension.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Liraglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Liraglutide study, the assignments were hidden from both participants and investigators until the end.

Some patients received a placebo instead of Liraglutide, giving a reference point.

What Was Measured

The subject headings attached to it are Blood Glucose, Body Mass Index, Combined Modality Therapy, Counseling, Diarrhea, Diet, Reducing and Exercise.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Liraglutide in 3731 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2015 (The New England journal of medicine), a journal based in United States.

More context: the Liraglutide compound page.